- Home
- KLRS vs APT Comparison
KLRS vs APT Comparison
Compare KLRS & APT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- APT
- Stock Information
- Founded
- KLRS 2019
- APT 1983
- Country
- KLRS United States
- APT Canada
- Employees
- KLRS N/A
- APT N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- APT
- Sector
- KLRS Health Care
- APT
- Exchange
- KLRS Nasdaq
- APT Nasdaq
- Market Cap
- KLRS 46.0M
- APT 50.4M
- IPO Year
- KLRS N/A
- APT 1995
- Fundamental
- Price
- KLRS $4.97
- APT $4.66
- Analyst Decision
- KLRS Strong Buy
- APT
- Analyst Count
- KLRS 2
- APT 0
- Target Price
- KLRS $23.00
- APT N/A
- AVG Volume (30 Days)
- KLRS 175.7K
- APT 16.2K
- Earning Date
- KLRS 11-15-2025
- APT 11-06-2025
- Dividend Yield
- KLRS N/A
- APT N/A
- EPS Growth
- KLRS N/A
- APT N/A
- EPS
- KLRS N/A
- APT 0.33
- Revenue
- KLRS N/A
- APT $58,562,000.00
- Revenue This Year
- KLRS N/A
- APT N/A
- Revenue Next Year
- KLRS N/A
- APT N/A
- P/E Ratio
- KLRS N/A
- APT $14.03
- Revenue Growth
- KLRS N/A
- APT N/A
- 52 Week Low
- KLRS $2.14
- APT $4.06
- 52 Week High
- KLRS $24.15
- APT $6.20
- Technical
- Relative Strength Index (RSI)
- KLRS 49.92
- APT 46.83
- Support Level
- KLRS $4.70
- APT $4.60
- Resistance Level
- KLRS $5.30
- APT $4.71
- Average True Range (ATR)
- KLRS 0.41
- APT 0.10
- MACD
- KLRS -0.06
- APT 0.00
- Stochastic Oscillator
- KLRS 67.48
- APT 42.86
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About APT Alpha Pro Tech Ltd.
Alpha Pro Tech Ltd is in the business of protecting people, products and environments. It is developing, manufacturing and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical and dental markets. It also manufacture a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply: consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment and synthetic roof underlayment accessories.